Last reviewed · How we verify

Administration of Corneal Anesthesia — Treatment Landscape & Competitive Intelligence

Administration of Corneal Anesthesia (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Administration of Corneal Anesthesia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Tetracaine Hydrochloride TETRACAINE Alcon Labs Ester Local Anesthetic Sodium channel protein type 7 subunit alpha 2005-01-01
Proxymetacaine Proxymetacaine Medical University of Silesia Amine oxidase [flavin-containing] A, Sigma non-opioid intracellular receptor 1, Sodium channel protein type 10 subunit alpha

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Alcon Labs · 1 drug in Administration of Corneal Anesthesia
  2. Medical University of Silesia · 1 drug in Administration of Corneal Anesthesia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Administration of Corneal Anesthesia:

Cite this brief

Drug Landscape (2026). Administration of Corneal Anesthesia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/administration-of-corneal-anesthesia. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing